Research view
Switch to patient viewColorectal cancer: trials that stopped early
Trials on Colorectal cancer that stopped early, each with the reason the sponsor wrote in the registry, quoted word for word. Next to them: finished trials whose registry record links a result paper.
Stopped early
254 stopped trials give a reason in the registry, latest registry update first. 4 more give no reason and are not listed.
Terminated
A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway
Reason given in the registry “business objectives have changed”
Quoted unchanged from ClinicalTrials.gov; record updated 19 Feb 2026.
- Ended
- Feb 2026
- Phase
- Phase 1
- Run by
- Mirati Therapeutics Inc.
- Registry record
- NCT05578092
Withdrawn
Immunotherapies in Combination With Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC)
Reason given in the registry “The trial is closing due to findings from a related study, prompting the sponsor to discontinue development and end this study.”
Quoted unchanged from ClinicalTrials.gov; record updated 19 Feb 2026.
- Ended
- Aug 2025
- Phase
- Phase 2
- Run by
- National Cancer Institute (NCI)
- Registry record
- NCT06603818
Terminated
Liver Surgery and Chemotherapy in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery and Lung Metastases That Cannot Be Removed by Surgery
Reason given in the registry “\< 75% participation”
Quoted unchanged from ClinicalTrials.gov; record updated 17 Feb 2026.
- Ended
- Dec 2025
- Phase
- Phase 2
- Run by
- M.D. Anderson Cancer Center
- Registry record
- NCT02738606
Withdrawn
Development, Implementation and Evaluation of an Individual Decision Aid in Swedish Cancer Screening Programs
Reason given in the registry “Lack of funding”
Quoted unchanged from ClinicalTrials.gov; record updated 11 Feb 2026.
- Ended
- Oct 2025
- Run by
- Karolinska Institutet
- Registry record
- NCT05512260
Withdrawn
Study of 5-fluorouracil (5-FU) in Patients With Metastatic Colorectal Cancer
Reason given in the registry “Principal Investigator has left Inova”
Quoted unchanged from ClinicalTrials.gov; record updated 11 Feb 2026.
- Ended
- Sept 2025
- Phase
- Phase 2
- Run by
- Inova Health Care Services
- Registry record
- NCT06501989
Withdrawn
A Study to Evaluate the Efficacy and Safety of Inavolisib When Administered in Combination With Bevacizumab and FOLFOX or FOLFIRI as First Line Therapy in Participants With Colorectal Cancer
Reason given in the registry “Sponsor's decision”
Quoted unchanged from ClinicalTrials.gov; record updated 9 Feb 2026.
- Phase
- Phase 2
- Run by
- Hoffmann-La Roche
- Registry record
- NCT07323576
Withdrawn
Living Donor Liver Transplantation for CRC Liver Metastases
Reason given in the registry “Slow accrual”
Quoted unchanged from ClinicalTrials.gov; record updated 6 Feb 2026.
- Run by
- University of Wisconsin, Madison
- Registry record
- NCT05175092
Terminated
A Research Study to Collect Patient Reported Outcomes Using Electronic Surveys
Reason given in the registry “Slow study accrual. Study sponsor decided to terminate the study in consultation with the DSMB.”
Quoted unchanged from ClinicalTrials.gov; record updated 5 Feb 2026.
- Ended
- Sept 2025
- Run by
- AHS Cancer Control Alberta
- Registry record
- NCT04990895
Suspended
Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients
Reason given in the registry “due to earlier termination of the agreement between the Sponsor and Central Laboratory for screening test. Enrollment will reopen as soon as a new laboratory is identified.”
Quoted unchanged from ClinicalTrials.gov; record updated 3 Feb 2026.
- Phase
- Phase 2
- Run by
- Gruppo Oncologico del Nord-Ovest
- Registry record
- NCT05062889
Terminated
RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC
Reason given in the registry “Business reasons.”
Quoted unchanged from ClinicalTrials.gov; record updated 2 Feb 2026.
- Ended
- Aug 2025
- Phase
- Phase 2
- Run by
- Replimune, Inc.
- Registry record
- NCT05733611
Terminated
Clinical Utility of Selected Circulating Tumor DNA Assays in Patients With Advanced Malignancy
Reason given in the registry “The platform used for detecting ctDNA was not sensitive enough.”
Quoted unchanged from ClinicalTrials.gov; record updated 29 Jan 2026.
- Ended
- Jul 2024
- Run by
- Oslo University Hospital
- Registry record
- NCT06290856
Terminated
A Study of PHN-010 in Patients With Advanced Solid Tumors
Reason given in the registry “The study was terminated by Sponsor for strategic reasons.”
Quoted unchanged from ClinicalTrials.gov; record updated 29 Jan 2026.
- Ended
- Sept 2025
- Phase
- Phase 1
- Run by
- Pheon Therapeutics
- Registry record
- NCT06457997
Terminated
Evaluation of the Efficacy of Two Guidance Techniques (Standard Injected CT vs Porto-scanner With Angio-CT) for Thermoablation Treatment of Colorectal Cancer Liver Metastases
Reason given in the registry “* Not enough inclusions * Montpellier is not included (0 inclusions) * Of the 7 patients included, there were recurrences in both groups, raising questions about the relevance of the study. * One serious complication in one group was reported.”
Quoted unchanged from ClinicalTrials.gov; record updated 23 Jan 2026.
- Ended
- Oct 2025
- Run by
- Centre Hospitalier Universitaire de Nīmes
- Registry record
- NCT05665322
Terminated
Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer
Reason given in the registry “Terminated per directive from Bayer due to funding.”
Quoted unchanged from ClinicalTrials.gov; record updated 20 Jan 2026.
- Ended
- Nov 2025
- Phase
- Phase 2
- Run by
- Anwaar Saeed
- Registry record
- NCT06006923
Terminated
Holmium-166 TARE in Liver Limited Unresectable Colorectal Cancer Patients
Reason given in the registry “Medical devices (QuiremScout/QuiremSpheres) no longer available due to discontinuation of production by the manufacturer”
Quoted unchanged from ClinicalTrials.gov; record updated 5 Jan 2026.
- Ended
- Dec 2025
- Phase
- Phase 2
- Run by
- Gruppo Oncologico del Nord-Ovest
- Registry record
- NCT06332079
Terminated
Glutamine PET Imaging Colorectal Cancer
Reason given in the registry “\<75% participation”
Quoted unchanged from ClinicalTrials.gov; record updated 2 Jan 2026.
- Ended
- Dec 2025
- Phase
- Phase 1
- Run by
- M.D. Anderson Cancer Center
- Registry record
- NCT03275974
Terminated
Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases
Reason given in the registry “Sponsor decision”
Quoted unchanged from ClinicalTrials.gov; record updated 31 Dec 2025.
- Ended
- Sept 2025
- Phase
- Phase 2
- Run by
- Chloe Atreya, MD, PhD
- Registry record
- NCT03844750
Withdrawn
STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma
Reason given in the registry “no resource”
Quoted unchanged from ClinicalTrials.gov; record updated 24 Dec 2025.
- Phase
- Phase 1
- Run by
- City of Hope Medical Center
- Registry record
- NCT06626256
Terminated
KZR-261 in Subjects With Advanced Solid Malignancies
Reason given in the registry “Sponsor decision.”
Quoted unchanged from ClinicalTrials.gov; record updated 19 Dec 2025.
- Ended
- Jan 2025
- Phase
- Phase 1
- Run by
- Kezar Life Sciences, Inc.
- Registry record
- NCT05047536
Suspended
Real-Time Feedback (RTFB) to Improve Colonoscopy
Reason given in the registry “we are on hold and may restart depending on a manual followed by automated assessment of existing files”
Quoted unchanged from ClinicalTrials.gov; record updated 9 Dec 2025.
- Run by
- University of Minnesota
- Registry record
- NCT05241210
Suspended
Preoperative ChemoRadiation And FOLFOXIRI for Rectal Cancer (CRAFTER) for Rectal Cancer
Reason given in the registry “no slots available”
Quoted unchanged from ClinicalTrials.gov; record updated 4 Dec 2025.
- Phase
- Phase 2
- Run by
- Rutgers, The State University of New Jersey
- Registry record
- NCT05358704
Terminated
A Phase I Clinical Study of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab Injection in Patients With Advanced Solid Tumors
Reason given in the registry “The trial was stopped early on the initiative of the sponsor on the basis of a change in the research and development strategy without safety concerns”
Quoted unchanged from ClinicalTrials.gov; record updated 3 Dec 2025.
- Ended
- Jan 2024
- Phase
- Phase 1
- Run by
- Shanghai Junshi Bioscience Co., Ltd.
- Registry record
- NCT05427396
Suspended
A Community-Based Educational Intervention to Improve Colorectal Cancer Screening
Reason given in the registry “staffing”
Quoted unchanged from ClinicalTrials.gov; record updated 28 Nov 2025.
- Ended
- Sept 2026
- Run by
- Thomas Jefferson University
- Registry record
- NCT04392050
Terminated
Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
Reason given in the registry “Sponsor decision”
Quoted unchanged from ClinicalTrials.gov; record updated 17 Nov 2025.
- Ended
- Aug 2025
- Phase
- Phase 1
- Run by
- Bolt Biotherapeutics, Inc.
- Registry record
- NCT06052852
Terminated
A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors
Reason given in the registry “Due to lack of expected efficacy shown at the time of the interim analysis”
Quoted unchanged from ClinicalTrials.gov; record updated 17 Nov 2025.
- Ended
- Nov 2024
- Phase
- Phase 2
- Run by
- SOTIO Biotech AG
- Registry record
- NCT05256381
Terminated
Informed Choice - Compass
Reason given in the registry “Business decision to terminate the study early. Primary endpoint will not be assessed.”
Quoted unchanged from ClinicalTrials.gov; record updated 10 Nov 2025.
- Ended
- Jan 2025
- Run by
- Exact Sciences Corporation
- Registry record
- NCT05246839
Terminated
Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors
Reason given in the registry “Recruitment challenges”
Quoted unchanged from ClinicalTrials.gov; record updated 29 Oct 2025.
- Ended
- Aug 2024
- Phase
- Phase 2
- Run by
- Tempus AI
- Registry record
- NCT05169437
Withdrawn
Combined AlloStim+Anti-PD-L1 in 4L MSS Metastatic Colorectal Cancer
Reason given in the registry “Redesign of protocol for primary end-point of overall survival”
Quoted unchanged from ClinicalTrials.gov; record updated 21 Oct 2025.
- Phase
- Phase 2
- Run by
- Mirror Biologics, Inc.
- Registry record
- NCT06557278
Terminated
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
Reason given in the registry “Sponsor's strategic business decision”
Quoted unchanged from ClinicalTrials.gov; record updated 15 Oct 2025.
- Ended
- Aug 2025
- Phase
- Phase 1
- Run by
- Actym Therapeutics, Inc.
- Registry record
- NCT06336148
Terminated
YASU Research Registry: For Young Adults With Cancer
Reason given in the registry “Sponsoring organization no longer desired to recruit/maintain registry”
Quoted unchanged from ClinicalTrials.gov; record updated 14 Oct 2025.
- Ended
- Sept 2025
- Run by
- Young Adult Survivors United
- Registry record
- NCT06275854
Sources: ClinicalTrials.gov and the EU Clinical Trials Register. Status, reason, dates and result links are registry fields, shown as the registry gives them.